MedTrace Logo

Drug-Drug Interaction Study in Healthy Subjects

NCT00904059 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2011-01-07

No results posted yet for this study

Summary

The purpose of this study is to assess the pharmacokinetics and safety of BMS-790052 and BMS-650032 when co-administered and when administered alone

Conditions

  • Hepatitis C

Interventions

DRUG

BMS-650032

Capsules, Oral, 600 mg, Q12h, Days 1-7

DRUG

BMS-790052

Capsules, Oral, 60 mg, Q24h, Days 1-7

DRUG

BMS-650032

Capsules, Oral, 200 mg, Q12h, Days 8-21

DRUG

BMS-790052

Capsules, Oral, 30 mg, Q24h, Days 8-21

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2009-07-31
Completion
2009-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00904059 on ClinicalTrials.gov